Myriad Genetics outlined a staged commercial plan for tissue‑informed MRD assays, beginning with a breast cancer MRD test in early 2026 and follow‑on launches for renal, colorectal, endometrial, and ovarian cancer through 2027. The company told investors and attendees at JP Morgan that it will seek MolDx coverage and run early‑access programs to build clinical utility evidence. Myriad also flagged a parallel strategy to expand its transcriptome platform with launches such as a sequencing‑based Prosigna and an AI‑enabled Prolaris update for prostate cancer. Management said these products, alongside a 20‑study MRD evidence base, are central to near‑term growth forecasts. The company emphasized reimbursement planning as essential; Myriad will aim to secure guideline inclusion and private payor coverage by generating prospective utility data.